200 related articles for article (PubMed ID: 29616706)
1. The Integrated Alzheimer's Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial.
Wessels AM; Andersen SW; Dowsett SA; Siemers ER
J Prev Alzheimers Dis; 2018; 5(2):134-136. PubMed ID: 29616706
[TBL] [Abstract][Full Text] [Related]
2. A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS).
Wessels AM; Siemers ER; Yu P; Andersen SW; Holdridge KC; Sims JR; Sundell K; Stern Y; Rentz DM; Dubois B; Jones RW; Cummings J; Aisen PS
J Prev Alzheimers Dis; 2015 Dec; 2(4):227-241. PubMed ID: 27019841
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
[TBL] [Abstract][Full Text] [Related]
4. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
Honig LS; Vellas B; Woodward M; Boada M; Bullock R; Borrie M; Hager K; Andreasen N; Scarpini E; Liu-Seifert H; Case M; Dean RA; Hake A; Sundell K; Poole Hoffmann V; Carlson C; Khanna R; Mintun M; DeMattos R; Selzler KJ; Siemers E
N Engl J Med; 2018 Jan; 378(4):321-330. PubMed ID: 29365294
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
[TBL] [Abstract][Full Text] [Related]
6. Statistical properties of continuous composite scales and implications for drug development.
Liu-Seifert H; Andersen S; Case M; Sparks J; Holdridge KC; Wessels AM; Hendrix S; Aisen P; Siemers E
J Biopharm Stat; 2017; 27(6):1104-1114. PubMed ID: 28402165
[TBL] [Abstract][Full Text] [Related]
7. Donanemab in Early Alzheimer's Disease.
Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
[TBL] [Abstract][Full Text] [Related]
8. Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease.
Liu-Seifert H; Case MG; Andersen SW; Holdridge KC; Aisen PS; Kollack-Walker S; Siemers E
J Prev Alzheimers Dis; 2018; 5(1):8-14. PubMed ID: 29405226
[TBL] [Abstract][Full Text] [Related]
9. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Liu-Seifert H; Siemers E; Price K; Han B; Selzler KJ; Henley D; Sundell K; Aisen P; Cummings J; Raskin J; Mohs R;
J Alzheimers Dis; 2015; 47(1):205-14. PubMed ID: 26402769
[TBL] [Abstract][Full Text] [Related]
10. Disease progression model using the integrated Alzheimer's Disease Rating Scale.
Gueorguieva I; Chua L; Willis BA; Sims JR; Wessels AM
Alzheimers Dement; 2023 Jun; 19(6):2253-2264. PubMed ID: 36450003
[TBL] [Abstract][Full Text] [Related]
11. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia.
Liu-Seifert H; Siemers E; Sundell K; Price K; Han B; Selzler K; Aisen P; Cummings J; Raskin J; Mohs R
J Alzheimers Dis; 2015; 43(3):949-55. PubMed ID: 25125457
[TBL] [Abstract][Full Text] [Related]
12. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
[TBL] [Abstract][Full Text] [Related]
13. Demonstration of Clinical Meaningfulness of the Integrated Alzheimer's Disease Rating Scale (iADRS): Association Between Change in iADRS Scores and Patient and Caregiver Health Outcomes.
Wessels AM; Belger M; Johnston JA; Yu Y; Rentz DM; Dowsett SA; Chandler J
J Alzheimers Dis; 2022; 88(2):577-588. PubMed ID: 35694928
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
15. Minimal clinically important difference in Alzheimer's disease: Rapid review.
Muir RT; Hill MD; Black SE; Smith EE
Alzheimers Dement; 2024 May; 20(5):3352-3363. PubMed ID: 38561021
[TBL] [Abstract][Full Text] [Related]
16. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
[TBL] [Abstract][Full Text] [Related]
17. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
18. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
Wessels AM; Dowsett SA; Sims JR
J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
[TBL] [Abstract][Full Text] [Related]
19. Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates.
Wessels AM; Rentz DM; Case M; Lauzon S; Sims JR
Alzheimers Dement (N Y); 2022; 8(1):e12312. PubMed ID: 35676941
[TBL] [Abstract][Full Text] [Related]
20. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease.
Bilikiewicz A; Gaus W
J Alzheimers Dis; 2004 Feb; 6(1):17-26. PubMed ID: 15004324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
